Acceleron Pharma Inc (XLRN) Receives Consensus Rating of “Hold” from Brokerages

Acceleron Pharma Inc (NASDAQ:XLRN) has been given an average rating of “Hold” by the twenty ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $46.33.

Several equities analysts have recently weighed in on the company. Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the company a “buy” rating in a report on Tuesday, November 14th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th.

In related news, SVP Christopher Rovaldi sold 11,000 shares of the firm’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $45.00, for a total value of $495,000.00. Following the transaction, the senior vice president now directly owns 35,701 shares of the company’s stock, valued at approximately $1,606,545. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jean George sold 105,122 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the transaction, the director now directly owns 1,250 shares in the company, valued at $44,662.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,021 shares of company stock worth $5,529,598. 3.90% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP raised its holdings in Acceleron Pharma by 416.3% in the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares during the period. Public Employees Retirement Association of Colorado bought a new position in Acceleron Pharma in the 4th quarter worth $138,000. Amalgamated Bank bought a new position in Acceleron Pharma in the 4th quarter worth $217,000. Oppenheimer & Co. Inc. bought a new position in Acceleron Pharma in the 3rd quarter worth $225,000. Finally, PNC Financial Services Group Inc. raised its holdings in Acceleron Pharma by 57.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares during the period. 85.81% of the stock is currently owned by institutional investors.

Acceleron Pharma (XLRN) traded up $0.49 during mid-day trading on Wednesday, reaching $41.47. The company had a trading volume of 304,000 shares, compared to its average volume of 315,141. The company has a market cap of $1,853.73, a PE ratio of -16.18 and a beta of 1.45. Acceleron Pharma has a fifty-two week low of $24.37 and a fifty-two week high of $46.93.

COPYRIGHT VIOLATION WARNING: This piece was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/14/acceleron-pharma-inc-xlrn-receives-consensus-rating-of-hold-from-brokerages.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply